Structure Therapeutics swings to profit in Q4

Structure Therapeutics

26/02/2026 21:31

Overview

Biopharmaceutical firm reported Q4 net income of $33 mln, reversing last year's loss

Company's R&D expenses rose significantly due to clinical trial costs and personnel expansion

Company holds $1.4 bln in cash, funding operations through 2028

Outlook

Structure Therapeutics expects to initiate aleniglipron Phase 3 trials in 2H 2026

Company plans Phase 1 study of ACCG-3535 in 2H 2026

Cash runway expected to fund operations through 2028

Result Drivers

OTHER LICENSE INCOME - Company reported $100 mln in other license income, related to license of certain patents that cover a class of oral GLP-1 receptor agonists that is different from aleniglipron

Company press release: ID:nGNX1kBFfH

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$141.20 mln
FY Income From Operations
-$176.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Structure Therapeutics Inc is $101.50, about 52.6% above its February 25 closing price of $66.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)